Skip to main content
. Author manuscript; available in PMC: 2019 Dec 19.
Published in final edited form as: JACC Cardiovasc Interv. 2016 Aug 22;9(16):1694–1702. doi: 10.1016/j.jcin.2016.05.039

TABLE 4.

Event Rates for Efficacy and Safety Endpoints According to Study Treatment Among PCI Patients

Unadjusted Event Rate/100 Patient-Years (No. of Events)
Endpoint Rivaroxaban (n ¼ 61) Warfarin (n ¼ 92)
Stroke or systemic embolism 5.0 (3) 4.1 (4)
Stroke 1.6 (1) 4.1 (4)
MI 6.8 (3) 5.9 (4)
Vascular death 3.1 (2) 11.1 (11)
Major or NMCR bleeding 57.7 (15) 20.3 (12)
Major bleeding 15.0 (6) 8.1 (6)

Abbreviation as in Tables 1 and 3.